Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21NO2.ClH |
| Molecular Weight | 331.836 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12CC3=C(C(O)=C(O)C=C3)C4=C1C(CCN2CCC)=CC=C4
InChI
InChIKey=PCOQOGIDTIFQAM-XFULWGLBSA-N
InChI=1S/C19H21NO2.ClH/c1-2-9-20-10-8-12-4-3-5-14-17(12)15(20)11-13-6-7-16(21)19(22)18(13)14;/h3-7,15,21-22H,2,8-11H2,1H3;1H/t15-;/m1./s1
| Molecular Formula | C19H21NO2 |
| Molecular Weight | 295.3755 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Propylnorapomorphine is a potent and selective D2 receptor agonist. Propylnorapomorphine is used as a tool compound to label dopamine receptors in rodent brain, and elicits dopaminergic behavioural effects. It stimulates motor activity, induces stereotypic behaviour and sexual stimulation. Propylnorapomorphine was investigated in clinical trial against Parkinson's disease and schizophrenia
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
10.12 null [pKi] | ||
Target ID: CHEMBL234 |
8.74 null [pKi] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P35462 Gene ID: 1814.0 Gene Symbol: DRD3 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. | 1979 Jul 1 |
|
| Potentiation of the aphrodisiac effect of N-n-propyl-norapomorphine by naloxone. | 1982 Jul 9 |
|
| Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines. | 1982 Oct |
|
| Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat. | 2011 Feb |
Patents
Sample Use Guides
In a clinical study against Parkinson's disease, propylnorapomorphine was administered orally. The most effect was observed at doses of 10 to 15 mg six time per day. In rodents, propylnorapomorphine is administered intraperitoneally.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:05 GMT 2023
by
admin
on
Fri Dec 15 15:26:05 GMT 2023
|
| Record UNII |
86EPT6U9AT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
20382-71-2
Created by
admin on Fri Dec 15 15:26:05 GMT 2023 , Edited by admin on Fri Dec 15 15:26:05 GMT 2023
|
PRIMARY | |||
|
DTXSID601017969
Created by
admin on Fri Dec 15 15:26:05 GMT 2023 , Edited by admin on Fri Dec 15 15:26:05 GMT 2023
|
PRIMARY | |||
|
3032728
Created by
admin on Fri Dec 15 15:26:05 GMT 2023 , Edited by admin on Fri Dec 15 15:26:05 GMT 2023
|
PRIMARY | |||
|
86EPT6U9AT
Created by
admin on Fri Dec 15 15:26:05 GMT 2023 , Edited by admin on Fri Dec 15 15:26:05 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |